Intelligence for the Molecular Frontier
Omix Core is Arche’s computational biology venture, built to accelerate the discovery of therapeutic targets and biosimilar molecules for pharmaceutical companies and biotech startups.
By combining AI-powered data mining, in-silico molecular simulation, and targeted in-vitro validation, Omix Core enables teams to identify, evaluate, and de-risk therapeutic candidates earlier—shortening discovery timelines and focusing R&D efforts on molecules with the highest probability of success.
Omix Core is not a drug developer. It is foundational infrastructure that supports and accelerates therapeutic R&D.
A SMARTER WAY TO DISCOVER THERAPEUTICS
Early therapeutic discovery remains constrained by fragmented data, manual screening, and costly trial-and-error experimentation. As molecular complexity increases, the need to narrow targets becomes essential. An AI-driven computational biology approach brings discovery upstream, transforming complexity into structured, evidence-based insight.
FASTER DECISION, LOWER RISK
We help pharmaceutical companies and biotech startups focus on molecules with the highest likelihood of success. By digitally identifying biosimilar candidates, simulating their behavior in-silico, and validating key properties in-vitro, Omix Core shortens discovery timelines, reduces early-stage risk, and enables faster, more confident go/no-go decisions—without disrupting existing R&D workflows.
ADVANCED THERAPEUTICS DISCOVERY
Molecular Intelligence for the Next Era of Therapeutics
At the core of Omix Core is the principle that therapeutic function can be defined as a set of molecular constraints. The platform applies AI-driven match-making to map therapeutic requirements—such as target engagement, binding affinity, stability, and selectivity—onto existing molecular space. By combining large-scale molecular datasets with computational modeling and structure-based inference, Omix Core prioritizes biosimilar and therapeutic candidates with the highest predicted functional relevance, enabling faster, more systematic progression into downstream R&D.
Helix is the first layer of Omix Core and focuses on the identification and prioritization of therapeutic targets, including enzymes, structural proteins, and membrane receptors. Once a disease area is defined by the customer, Helix performs AI-assisted data mining across scientific literature, patents, clinical databases, and regulatory sources to surface high-impact and actionable targets.
For each selected target, Helix builds a dedicated, continuously updated knowledge base capturing biological context, known mechanisms, existing therapeutics, and the current state of the art. This provides our customers with a structured, evidence-based foundation for downstream molecular discovery.
HELIX - AI POWERED TARGET DISCOVERY AND INTELLIGENCE
Axiom is the second layer of Omix Core and its core intelligence engine. It focuses on identifying therapeutic molecules capable of interacting effectively with the targets discovered by Helix.
Using advanced AI and computational modeling, Axiom explores large small-molecule and compound databases, analyzing constitutional, topological, geometric, and hybrid descriptors to simulate and predict target–molecule interactions. This enables systematic evaluation of candidate molecules based on predicted binding behavior, compatibility, and functional relevance.
Axiom allows customers to narrow vast molecular spaces into a focused set of high-confidence candidates before entering experimental validation and downstream R&D.
AXIOM - AI DRIVEN MOLECULAR DISCOVERY AND MODELING
Vera is Omix Core’s experimental validation layer, where computational predictions are tested against biological reality.
Selected candidates are validated in-vitro to confirm key predicted characteristics—such as binding behavior, functional response, or stability—before customers initiate broader R&D and development programs. Vera’s role is focused confirmation and de-risking, not full-scale discovery.
Results generated in Vera continuously strengthen Omix Core’s models, improving the accuracy and reliability of Axiom over time.
VERA - TRAGETED IN-VITRO VAIDATION
OMIX CORE
Accelerating Discovery with AI-Powered Computational Biology